Showing results (81-90 of 102) with videos related to

Sort By:
Pageof 11
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium StudyTimothy F Cloughesy, Patrick Y Wen, H Ian Robins, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
Neuro-Oncology|December 21, 2016
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813Susan Chang, Peixin Zhang, J Gregory Cairncross, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Brain Pathology (Zurich, Switzerland)|March 5, 2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous systemAditya Raghunathan, Khalida Wani, Terri S Armstrong, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Pageof 11